drugset / Trial / NCT07082179
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, multicenter, open-label, single-arm Phase II clinical trial. The study recruits patients with stage III unresectable non-small cell lung cancer according to the 8th edition of the AJCC/UICC staging system. It aims to observe and evaluate the efficacy and safety of anti-PD-1/CTLA-4 antibody in combination with paclitaxel polymer micelles and platinum-based therapy for stage III unresectable non-small cell lung cancer.
Timeline
- Start
- 2025-09-04
- Primary completion
- 2027-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apalotamab | Unknown | 5 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Cisplatin | Other / unclassified | 70 mg/m2 | — |
| Subject | Iparomlimab | Monoclonal antibody | — | — |
| Subject | Paclitaxel | Small molecule | 230 mg/m2 | Intravenous |
| Subject | Tuvonralimab | Monoclonal antibody | — | — |